A. Abukanna, Ziyad Mubarak S Alanazi, Amer Alanazi, A. Alenazi, Abdulrahman Obaid A Alanazi, Khaloud Attaulla Alenezi, G. M. Alsalmi
{"title":"Obesity as a Risk Factor for Different Cancers: Systematic Review","authors":"A. Abukanna, Ziyad Mubarak S Alanazi, Amer Alanazi, A. Alenazi, Abdulrahman Obaid A Alanazi, Khaloud Attaulla Alenezi, G. M. Alsalmi","doi":"10.51847/k1awbiln5t","DOIUrl":"https://doi.org/10.51847/k1awbiln5t","url":null,"abstract":"","PeriodicalId":44457,"journal":{"name":"Clinical Cancer Investigation Journal","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70826130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abdulraheem Donkol, Rawan A Alsomali, Ahmed Mohammed Alshammari, Hussain Alkhamis, Lama K Alharbi, A. Alhazmi, Abdullah Ahmad Mahdi Daiel, Dawoud Abdullah Mohammed Mohzari, Ahmed Jamal Hejres, Naif Abdulmajeed AlRefaei, Batool Mohammed S. Alshehri
The current review is about Colorectal Cancer (CRC) which is the third most prevalent malignancy and the fourth most frequent cause of cancer-related death. However, only 1% to 4% of incidences are documented in people between the ages of 25 and 30. A family history of colon or rectal cancer, diet, alcohol consumption, smoking, and inflammatory bowel disease are some risk factors for Colorectal Cancer. Various database including the Medline, Pubmed, Embase, NCBI, and Cochrane databases were searched for studies of patients with non-alcoholic fatty liver disease. Incidence, etiology, and management options were analyzed. It is uncommon for CRC to occur in children, adolescents, or young adults. Although the presenting symptoms are comparable to those in adults, CRC is frequently overlooked in a young patient's initial assessment. According to the results of the researches, surgery is the cornerstone of treatment, and patients who cannot be made disease-free through surgery are rarely cured.
{"title":"Review on Diagnosis and Management of Colorectal Carcinoma","authors":"Abdulraheem Donkol, Rawan A Alsomali, Ahmed Mohammed Alshammari, Hussain Alkhamis, Lama K Alharbi, A. Alhazmi, Abdullah Ahmad Mahdi Daiel, Dawoud Abdullah Mohammed Mohzari, Ahmed Jamal Hejres, Naif Abdulmajeed AlRefaei, Batool Mohammed S. Alshehri","doi":"10.51847/dxsj8lrq5w","DOIUrl":"https://doi.org/10.51847/dxsj8lrq5w","url":null,"abstract":"The current review is about Colorectal Cancer (CRC) which is the third most prevalent malignancy and the fourth most frequent cause of cancer-related death. However, only 1% to 4% of incidences are documented in people between the ages of 25 and 30. A family history of colon or rectal cancer, diet, alcohol consumption, smoking, and inflammatory bowel disease are some risk factors for Colorectal Cancer. Various database including the Medline, Pubmed, Embase, NCBI, and Cochrane databases were searched for studies of patients with non-alcoholic fatty liver disease. Incidence, etiology, and management options were analyzed. It is uncommon for CRC to occur in children, adolescents, or young adults. Although the presenting symptoms are comparable to those in adults, CRC is frequently overlooked in a young patient's initial assessment. According to the results of the researches, surgery is the cornerstone of treatment, and patients who cannot be made disease-free through surgery are rarely cured.","PeriodicalId":44457,"journal":{"name":"Clinical Cancer Investigation Journal","volume":"57 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70818899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Suraksha Sharma, Parbati Thapa Magar, Suchana Achhami, Pradip Hamal, Bipin Chapagain, S. Jaiswal, B. Tiwari
The study aimed to assess the bacterial profile and antibiotic resistance pattern among cancer patients attending B.P Koirala Memorial Cancer Hospital, Bharatpur, Chitwan. Hospital-based cross-sectional studies were carried out on 384 samples collected from cancer patients and were processed. After the growth of the organism on different media, Grams staining was done for primary identification and later identified by biochemical characteristics and was processed for antibiotic susceptibility by Kirby-Bauer method of disk diffusion and was reported sensitive or resistant by measuring zone of inhibition following the CLSI guideline (2020). The collected data were analyzed using SPSS V20.0. Out of 384 participants, 55.4% were male and 44.6% were female. Growth was found in 43.5% of specimens. Hematogenous cancer growth was 40.7% while 45.5% of growth was among non-hematogenous cancer patients. Escherichia coli were reported 38.9%, Klebsiella spp . 20.4%. Pseudomonas spp. 19.2%, Citrobacter spp . with 9.0%, and Acinetobacter spp . with 4.8%. Like-wise Staphylococcus aureus and Enterobacter aerogenes contributed 3.6% and 3.0% respectively. Proteus spp and CoNS were 0.6% each. E.coli was found to be highly resistant to Amoxycillin (98.5%), followed by Ciprofloxacin (73.9%) and then Cotrimoxazole (67.7%) while low resistance was found to Amikacin. Staphylococcus aureus was the most prevalent Gram-positive found to be 100% resistant to Amoxycillin, Ciprofloxacin, Cloxacillin, and Cephalexin i.e; 66.7% each and fully sensitive to Amikacin and Tigecycline. Gram-negative bacteria were more frequently isolated than gram-positive bacteria. Many opportunistic pathogens including MDR strains may readily infect patients with cancer.
{"title":"Bacterial profiling and antibiotic-resistant pattern among cancer patients","authors":"Suraksha Sharma, Parbati Thapa Magar, Suchana Achhami, Pradip Hamal, Bipin Chapagain, S. Jaiswal, B. Tiwari","doi":"10.51847/qkqoeuw5wi","DOIUrl":"https://doi.org/10.51847/qkqoeuw5wi","url":null,"abstract":"The study aimed to assess the bacterial profile and antibiotic resistance pattern among cancer patients attending B.P Koirala Memorial Cancer Hospital, Bharatpur, Chitwan. Hospital-based cross-sectional studies were carried out on 384 samples collected from cancer patients and were processed. After the growth of the organism on different media, Grams staining was done for primary identification and later identified by biochemical characteristics and was processed for antibiotic susceptibility by Kirby-Bauer method of disk diffusion and was reported sensitive or resistant by measuring zone of inhibition following the CLSI guideline (2020). The collected data were analyzed using SPSS V20.0. Out of 384 participants, 55.4% were male and 44.6% were female. Growth was found in 43.5% of specimens. Hematogenous cancer growth was 40.7% while 45.5% of growth was among non-hematogenous cancer patients. Escherichia coli were reported 38.9%, Klebsiella spp . 20.4%. Pseudomonas spp. 19.2%, Citrobacter spp . with 9.0%, and Acinetobacter spp . with 4.8%. Like-wise Staphylococcus aureus and Enterobacter aerogenes contributed 3.6% and 3.0% respectively. Proteus spp and CoNS were 0.6% each. E.coli was found to be highly resistant to Amoxycillin (98.5%), followed by Ciprofloxacin (73.9%) and then Cotrimoxazole (67.7%) while low resistance was found to Amikacin. Staphylococcus aureus was the most prevalent Gram-positive found to be 100% resistant to Amoxycillin, Ciprofloxacin, Cloxacillin, and Cephalexin i.e; 66.7% each and fully sensitive to Amikacin and Tigecycline. Gram-negative bacteria were more frequently isolated than gram-positive bacteria. Many opportunistic pathogens including MDR strains may readily infect patients with cancer.","PeriodicalId":44457,"journal":{"name":"Clinical Cancer Investigation Journal","volume":"15 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70831220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D. Pruthi, P. Nagpal, Ashu Yadav, Babita Bansal, Manish Pandey, N. Agarwal
Cancer is considered to be an age related disease because the incidence of most types of cancers increases with age rising more rapidly beginning in midlife. Adolescents and young adults are a distinct population, which is not a usual age for diagnosis of tumors that are usually found in older adults. Tumors in this group of patients tend to be different from tumors found in children or older adults. The treatment of such patients is challenging as they are at a higher risk of developing long-term side effects. In this case series, we report 3 cases of adult cancers that presented at an unusually younger age highlighting the fact that there is a recent shift in paradigm in terms of age of presentation of cancer. We present 3 cases namely, supraglottic larynx squamous cell carcinoma in a 21-year-old female, adenocarcinoma of the rectum in a 22-year-old male, and adenocarcinoma of the stomach and gastro-esophageal junction in a 25-year-old male. With this case series we want to highlight this recent change in the age presentation of adult cancers and this could foreshadow the future trend of the disease.
{"title":"Shifting Paradigm of Adult Cancers at Young Age –A Case Series","authors":"D. Pruthi, P. Nagpal, Ashu Yadav, Babita Bansal, Manish Pandey, N. Agarwal","doi":"10.51847/wxhwcy0kxx","DOIUrl":"https://doi.org/10.51847/wxhwcy0kxx","url":null,"abstract":"Cancer is considered to be an age related disease because the incidence of most types of cancers increases with age rising more rapidly beginning in midlife. Adolescents and young adults are a distinct population, which is not a usual age for diagnosis of tumors that are usually found in older adults. Tumors in this group of patients tend to be different from tumors found in children or older adults. The treatment of such patients is challenging as they are at a higher risk of developing long-term side effects. In this case series, we report 3 cases of adult cancers that presented at an unusually younger age highlighting the fact that there is a recent shift in paradigm in terms of age of presentation of cancer. We present 3 cases namely, supraglottic larynx squamous cell carcinoma in a 21-year-old female, adenocarcinoma of the rectum in a 22-year-old male, and adenocarcinoma of the stomach and gastro-esophageal junction in a 25-year-old male. With this case series we want to highlight this recent change in the age presentation of adult cancers and this could foreshadow the future trend of the disease.","PeriodicalId":44457,"journal":{"name":"Clinical Cancer Investigation Journal","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70839471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I. Dogan, N. Khanmammadov, Melin Aydan Ahmed, Anıl Yıldız, P. Saip, A. Aydıner, S. Vatansever
The goal of this study was to evaluate the efficacy of crizotinib in patients with ALK-positive metastatic lung cancer. The patients' data were analyzed retrospectively. Cox regression and Kaplan-Meier methods were used to perform survival analyses. A total of 25 patients were involved in the study. Thirteen (52%) patients were male, and the average age was 55 (range, 30-80). 23 (92%) of the patients were de-novo metastatic. Brain metastases were present in 32% and liver metastases in 20% of the patients. Before crizotinib treatment, 64% of the patients had received chemotherapy, and 20% had received palliative radiotherapy. Progression-free survival was found as 16.8 (CI 95%, 5.7-27.9) months. Grade 1-2 side effects were detected in 36% of the patients, and grade 3-4 side effects were observed in 12%. After progression, 13 (52%) patients received 2nd series ALK inhibitors (alectinib, ceritinib, and lorlatinib) or chemotherapy. The median overall survival (OS) was found as 44.2 (95% CI, 28.5-59.9) months. The four-year OS rate was 37.4%. In the multivariate analysis, the ALK positivity ratio (p=0.02) was determined as a statistically significant factor affecting OS. We showed efficacy data of crizotinib in patients with ALK mutant metastatic non-small cell lung cancer. Crizotinib is an effective and safe therapy for patients with ALK mutant metastatic non-small cell lung cancer. Also, we found that the ALK positivity ratio was prognostic for OS.
{"title":"Crizotinib in Metastatic ALK mutant Non-small Cell Lung Cancer Patients: A Single Centre Experience","authors":"I. Dogan, N. Khanmammadov, Melin Aydan Ahmed, Anıl Yıldız, P. Saip, A. Aydıner, S. Vatansever","doi":"10.51847/87n2fddtb1","DOIUrl":"https://doi.org/10.51847/87n2fddtb1","url":null,"abstract":"The goal of this study was to evaluate the efficacy of crizotinib in patients with ALK-positive metastatic lung cancer. The patients' data were analyzed retrospectively. Cox regression and Kaplan-Meier methods were used to perform survival analyses. A total of 25 patients were involved in the study. Thirteen (52%) patients were male, and the average age was 55 (range, 30-80). 23 (92%) of the patients were de-novo metastatic. Brain metastases were present in 32% and liver metastases in 20% of the patients. Before crizotinib treatment, 64% of the patients had received chemotherapy, and 20% had received palliative radiotherapy. Progression-free survival was found as 16.8 (CI 95%, 5.7-27.9) months. Grade 1-2 side effects were detected in 36% of the patients, and grade 3-4 side effects were observed in 12%. After progression, 13 (52%) patients received 2nd series ALK inhibitors (alectinib, ceritinib, and lorlatinib) or chemotherapy. The median overall survival (OS) was found as 44.2 (95% CI, 28.5-59.9) months. The four-year OS rate was 37.4%. In the multivariate analysis, the ALK positivity ratio (p=0.02) was determined as a statistically significant factor affecting OS. We showed efficacy data of crizotinib in patients with ALK mutant metastatic non-small cell lung cancer. Crizotinib is an effective and safe therapy for patients with ALK mutant metastatic non-small cell lung cancer. Also, we found that the ALK positivity ratio was prognostic for OS.","PeriodicalId":44457,"journal":{"name":"Clinical Cancer Investigation Journal","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70814997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Oral cancer is one of the most common types of cancer, and it is a big health issue, especially in developing countries. Even though science has come a long way in various ways, it is still one of the leading causes of death. In many developing countries, smoking and drinking alcohol seem to be the main things that cause oral cancer. Oral cancer (OC) is the most common type of cancer in India. It causes 50–70% of all cancer deaths and has the highest rate of occurrence among Asian countries. Most of the time, oral cancer affects the front of the tongue, the cheek, the floor of the mouth, the gums, or any other part of the mouth, including the palate, the lip, and the floor of the mouth. There are a lot of differences in how often oral cancer happens around the world. The biggest cause of oral disease-related deaths worldwide is estimated to be oral cancer, which is a serious health concern.
{"title":"The Current Scenario Regarding the Narrative Advancement of Oral Cancer","authors":"K. Jayavel, Sivakrishnan Sivagnanam","doi":"10.51847/fehfvfwasl","DOIUrl":"https://doi.org/10.51847/fehfvfwasl","url":null,"abstract":"Oral cancer is one of the most common types of cancer, and it is a big health issue, especially in developing countries. Even though science has come a long way in various ways, it is still one of the leading causes of death. In many developing countries, smoking and drinking alcohol seem to be the main things that cause oral cancer. Oral cancer (OC) is the most common type of cancer in India. It causes 50–70% of all cancer deaths and has the highest rate of occurrence among Asian countries. Most of the time, oral cancer affects the front of the tongue, the cheek, the floor of the mouth, the gums, or any other part of the mouth, including the palate, the lip, and the floor of the mouth. There are a lot of differences in how often oral cancer happens around the world. The biggest cause of oral disease-related deaths worldwide is estimated to be oral cancer, which is a serious health concern.","PeriodicalId":44457,"journal":{"name":"Clinical Cancer Investigation Journal","volume":"26 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70820524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Colorectal carcinoma (CRC) is one of the most common malignant neoplasms with significant morbidity and mortality worldwide. Cancer stem cell hypotheses have gathered significant attention to their molecular progression. CD44, a stem cell marker, is reported to be more concentrated in the malignant and premalignant cells. We aimed to study the prognostic and therapeutic utility of CD 44 in colorectal adenoma with low/high-grade dysplasia and carcinoma and its correlation with clinicopathological parameters. Histological examination was performed according to the criteria outlined in the World Health Organization Classification of tumors 2019 and AJCC 8 th edition. RAmbispective analysis of colorectal neoplasms yielded 50 cases, of which 30 were malignant. Positive staining and high expression of CD44 were more frequent in carcinoma than in adenoma. Further staining and expression were higher in adenoma with high-grade dysplasia than in adenoma with low-grade dysplasia (p value=0.021). A significant statistical correlation was noted in CRC cases with younger age (0.0006), increased mitosis (0.038), and higher AJCC stage (0.014). Our study suggests that CD 44 expression perhaps is higher in adenomas with high-grade dysplasia and CRC with higher pathological stage, and thus could predict a worse prognosis. Larger multi-institutional studies might help study its role as a prognostic and therapeutic stem cell marker.
{"title":"Evaluation and Clinicopathological Correlation of CD44 in Colorectal Adenoma with Low/High-Grade Dysplasia and Carcinoma","authors":"Himanshi Bhanu, R. Mittal, S. Raman","doi":"10.51847/q4yjbhtgzg","DOIUrl":"https://doi.org/10.51847/q4yjbhtgzg","url":null,"abstract":"Colorectal carcinoma (CRC) is one of the most common malignant neoplasms with significant morbidity and mortality worldwide. Cancer stem cell hypotheses have gathered significant attention to their molecular progression. CD44, a stem cell marker, is reported to be more concentrated in the malignant and premalignant cells. We aimed to study the prognostic and therapeutic utility of CD 44 in colorectal adenoma with low/high-grade dysplasia and carcinoma and its correlation with clinicopathological parameters. Histological examination was performed according to the criteria outlined in the World Health Organization Classification of tumors 2019 and AJCC 8 th edition. RAmbispective analysis of colorectal neoplasms yielded 50 cases, of which 30 were malignant. Positive staining and high expression of CD44 were more frequent in carcinoma than in adenoma. Further staining and expression were higher in adenoma with high-grade dysplasia than in adenoma with low-grade dysplasia (p value=0.021). A significant statistical correlation was noted in CRC cases with younger age (0.0006), increased mitosis (0.038), and higher AJCC stage (0.014). Our study suggests that CD 44 expression perhaps is higher in adenomas with high-grade dysplasia and CRC with higher pathological stage, and thus could predict a worse prognosis. Larger multi-institutional studies might help study its role as a prognostic and therapeutic stem cell marker.","PeriodicalId":44457,"journal":{"name":"Clinical Cancer Investigation Journal","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70830972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mata Uvaysovna Razhaeva, Linda Ahmedovna Khuchieva, Said-Akhmed AlMirzoevich Musaev, Alder Kamilevich Rustamov, Khadizhat Shepaevna Bicherkaeva, Khava Saidkhuseinovna Usmanova
Today, more than two and a half thousand compounds are known that are used in the production of food products. This is usually done to increase the preservation and storage period and improve organoleptic parameters. However, some of these toxic compounds may inadvertently enter food through packaging material and technological additives. Residues of toxic chemicals and industrial pollutants in food are a serious problem for a healthy body, which can lead to oncogenetic processes. Among such persistent organic pollutants are organochlorine pesticides, polychlorinated biphenyls, as well as by-products of chemical production and combustion processes, such as dioxins and furans. One of the most toxic pesticides is the organochlorine pesticide γ-isomer of hexachlorocyclohexane (C6H6Cl6). Pure hexachlorocyclohexane is a hydrophobic white powder with a crystalline structure that has strong acid-resistant parameters. To date, it is known for sure that hexachlorocyclohexane is a polytropic toxic chemical that primarily affects the central and autonomic nervous system of mammals. Hexachlorocyclohexane has been widely used in agriculture for pest control. Now the substance is banned everywhere. This article is devoted to the effect of hexachlorocyclohexane on the human body.
{"title":"Y-isomer of Hexachlorocyclohexane (C6H6Cl6) in Modern Human Life and Its Influence on the Processes of Oncogenesis","authors":"Mata Uvaysovna Razhaeva, Linda Ahmedovna Khuchieva, Said-Akhmed AlMirzoevich Musaev, Alder Kamilevich Rustamov, Khadizhat Shepaevna Bicherkaeva, Khava Saidkhuseinovna Usmanova","doi":"10.51847/wmbaexcxiy","DOIUrl":"https://doi.org/10.51847/wmbaexcxiy","url":null,"abstract":"Today, more than two and a half thousand compounds are known that are used in the production of food products. This is usually done to increase the preservation and storage period and improve organoleptic parameters. However, some of these toxic compounds may inadvertently enter food through packaging material and technological additives. Residues of toxic chemicals and industrial pollutants in food are a serious problem for a healthy body, which can lead to oncogenetic processes. Among such persistent organic pollutants are organochlorine pesticides, polychlorinated biphenyls, as well as by-products of chemical production and combustion processes, such as dioxins and furans. One of the most toxic pesticides is the organochlorine pesticide γ-isomer of hexachlorocyclohexane (C6H6Cl6). Pure hexachlorocyclohexane is a hydrophobic white powder with a crystalline structure that has strong acid-resistant parameters. To date, it is known for sure that hexachlorocyclohexane is a polytropic toxic chemical that primarily affects the central and autonomic nervous system of mammals. Hexachlorocyclohexane has been widely used in agriculture for pest control. Now the substance is banned everywhere. This article is devoted to the effect of hexachlorocyclohexane on the human body.","PeriodicalId":44457,"journal":{"name":"Clinical Cancer Investigation Journal","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70838860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L. Figueroa-Valverde, M. Rosas-Nexticapa, Magdalena Alvarez-Ramirez, M. Lopez-Ramos, Virginia Mateu-Armand
There are several drugs to treat cancer; nevertheless, some can produce adverse effects, such as hypertension, hepatic injury, and erectile dysfunction. In the search for new therapeutic alternatives, some Dibenzo derivatives have been used for treating cancer; however, other data suggest that Dibenzo derivatives can increase this clinical pathology. All these data are confusing; perhaps this phenomenon is due to the different chemical structures of each Dibenzo-derivative. Analyzing this data, this research aimed to evaluate the possible interaction of some Dibenzo derivatives (compounds 1 to 15) on some biomolecules involved in prostate cancer, such as androgen receptor and 5 α -reductase enzyme using flutamide, dutasteride, and finasteride drugs as theoretical tools in a Docking model. The results showed that some Dibenzo derivatives (9, 11, and 15) could interact with the androgen receptor surface. Besides, the Dibenzo derivatives 2, 5, and 13 may interact with the 5 α -reductase enzyme surface. In conclusion, these data suggest that some Dibenzo derivatives could be good candidates for the treatment of prostate cancer.
{"title":"Theoretical evaluation of interaction of some dibenzo derivatives on both androgen receptor and 5α-reductase enzyme","authors":"L. Figueroa-Valverde, M. Rosas-Nexticapa, Magdalena Alvarez-Ramirez, M. Lopez-Ramos, Virginia Mateu-Armand","doi":"10.51847/fivmfela7i","DOIUrl":"https://doi.org/10.51847/fivmfela7i","url":null,"abstract":"There are several drugs to treat cancer; nevertheless, some can produce adverse effects, such as hypertension, hepatic injury, and erectile dysfunction. In the search for new therapeutic alternatives, some Dibenzo derivatives have been used for treating cancer; however, other data suggest that Dibenzo derivatives can increase this clinical pathology. All these data are confusing; perhaps this phenomenon is due to the different chemical structures of each Dibenzo-derivative. Analyzing this data, this research aimed to evaluate the possible interaction of some Dibenzo derivatives (compounds 1 to 15) on some biomolecules involved in prostate cancer, such as androgen receptor and 5 α -reductase enzyme using flutamide, dutasteride, and finasteride drugs as theoretical tools in a Docking model. The results showed that some Dibenzo derivatives (9, 11, and 15) could interact with the androgen receptor surface. Besides, the Dibenzo derivatives 2, 5, and 13 may interact with the 5 α -reductase enzyme surface. In conclusion, these data suggest that some Dibenzo derivatives could be good candidates for the treatment of prostate cancer.","PeriodicalId":44457,"journal":{"name":"Clinical Cancer Investigation Journal","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70820620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nishant Lohia, Harish Sadashiva, Sankalp Singh, S. Agarwal, Vikas Gupta, Manoj Prashar, G. Trivedi
Nasal cavity as the first site of metastases from colorectal adenocarcinoma without metastases elsewhere is generally unheard of and very rare with only a few cases reported in world literature. The diagnostic dilemma and therapeutic challenge are significant when encountered in clinical practice, especially to differentiate it from a primary nasal pathology. Histopathological examination and immunohistochemistry play an important role. We report an unusual and interesting case of adenocarcinoma rectum with nasal metastases. A 65-year-old male was treated for adenocarcinoma rectum with radiotherapy, surgery and chemotherapy and was disease-free for 9 months post-treatment completion. Subsequently, he presented with nasal bleeding and on evaluation was found to have a nasal mass. Histopathological examination and immunohistochemistry confirmed the mass to be a metastasis from the earlier rectal adenocarcinoma. He received palliative haemostatic radiotherapy for bleeding from the nasal mass and was then treated with 6 cycles of 5-fluorouracil and irinotecan-based palliative chemotherapy. The patient achieved a good level of palliation, had near-complete regression of nasal mass on imaging with no new sites of metastases and hence was placed on regular follow up.
{"title":"A Very Rare Case of Metastases to the Nasal Cavity from Primary Rectal Adenocarcinoma","authors":"Nishant Lohia, Harish Sadashiva, Sankalp Singh, S. Agarwal, Vikas Gupta, Manoj Prashar, G. Trivedi","doi":"10.51847/gehiwxwo0s","DOIUrl":"https://doi.org/10.51847/gehiwxwo0s","url":null,"abstract":"Nasal cavity as the first site of metastases from colorectal adenocarcinoma without metastases elsewhere is generally unheard of and very rare with only a few cases reported in world literature. The diagnostic dilemma and therapeutic challenge are significant when encountered in clinical practice, especially to differentiate it from a primary nasal pathology. Histopathological examination and immunohistochemistry play an important role. We report an unusual and interesting case of adenocarcinoma rectum with nasal metastases. A 65-year-old male was treated for adenocarcinoma rectum with radiotherapy, surgery and chemotherapy and was disease-free for 9 months post-treatment completion. Subsequently, he presented with nasal bleeding and on evaluation was found to have a nasal mass. Histopathological examination and immunohistochemistry confirmed the mass to be a metastasis from the earlier rectal adenocarcinoma. He received palliative haemostatic radiotherapy for bleeding from the nasal mass and was then treated with 6 cycles of 5-fluorouracil and irinotecan-based palliative chemotherapy. The patient achieved a good level of palliation, had near-complete regression of nasal mass on imaging with no new sites of metastases and hence was placed on regular follow up.","PeriodicalId":44457,"journal":{"name":"Clinical Cancer Investigation Journal","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70821313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：